文献速递乳腺乳腺X线

起源于终末导管小叶单元的乳腺癌:乳腺原位与浸润性腺泡腺癌(AAB)

Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB.
PubMed 文献 · Eur J Radiol · 2022-05-10

该研究基于瑞典一项随机对照乳腺X线筛查试验超过四十年的随访数据及后续服务筛查项目,将起源于终末导管小叶单元(TDLU)的乳腺癌大体积厚切片与薄切片病理图像与乳腺X线肿瘤特征(影像生物标志物)及长期结局进行关联。结果显示影像生物标志物可可靠判断TDLU起源乳腺癌的部位,原位癌表现为粉末状或碎石样钙化,浸润癌表现为星芒状/毛刺状或圆形/卵圆形肿块,作者提出将其命名为乳腺腺泡腺癌(AAB)。

要点

  • TDLU起源原位癌的乳腺X线特征为粉末状或碎石样钙化,浸润癌为星芒状/毛刺状或圆形/卵圆形肿块。
  • 这些特征可单独或组合、单灶或多灶出现,乳腺影像易于识别。
  • 直径<15 mm且无大乳管起源癌(DAB)的AAB长期结局良好至极佳,常规预后因素(含免疫组化标志物)未能识别最终致命的1–14 mm浸润性AAB。

核心结论

  • 影像生物标志物可可靠判断起源于TDLU的乳腺癌的部位,作者提出将其命名为乳腺腺泡腺癌(AAB)。
  • 起源于TDLU的浸润癌无论WHO组织病理学术语如何复杂,均表现为星芒状/毛刺状或圆形。
  • 乳腺X线筛查带来的死亡率下降主要通过发现并治疗不可触及的早期AAB实现。
  • 直径<15 mm且无大乳管起源癌(DAB)的AAB长期结局良好至极佳,而现行术语倾向于导致这些早期浸润性肿瘤过度治疗。
  • 常规预后因素(包括免疫组化生物标志物)未能识别最终致命的1–14 mm浸润性AAB,术前纳入特征性乳腺X线肿瘤特征(影像生物标志物)可在原发诊断、治疗计划和预测长期结局中实现识别。

研究设计与样本

  • 研究类型为前瞻性收集数据的随机对照乳腺X线筛查试验(随访超过四十年)及瑞典达拉纳县后续基于人群的服务筛查项目数据库。
  • 研究对象为不可触及、主要为筛查检出的乳腺癌最早可检测阶段病例。
  • 方法为将起源于TDLU的乳腺癌大体积厚切片(亚宏观)与薄切片组织病理学图像与其乳腺X线肿瘤特征(影像生物标志物)及患者长期结局进行关联。
  • 原文未报告样本量、中心数及具体设备/序列信息。

关键影像表现/征象

  • 起源于TDLU的原位癌在乳腺X线上表现为粉末状或碎石样钙化。
  • 起源于TDLU的浸润癌在乳腺X线上表现为星芒状/毛刺状或圆形/卵圆形肿块。
  • 上述特征可单独或组合出现,可为单灶或多灶。

诊断标准与关键数值

  • 起源于TDLU的原位癌影像学标准为粉末状或碎石样钙化。
  • 起源于TDLU的浸润癌影像学标准为星芒状/毛刺状或圆形/卵圆形肿块。
  • 直径<15 mm且无大乳管起源癌(DAB)的AAB长期结局良好至极佳。
  • 常规预后因素(包括免疫组化生物标志物)未能识别最终致命的1–14 mm浸润性AAB。

临床应用与阅片要点

  • 作者提出可将特征性乳腺X线肿瘤特征(影像生物标志物)纳入原发诊断、治疗计划和长期结局预测,以术前识别最终致命的1–14 mm浸润性AAB。
  • 作者认为现行组织病理学术语将TDLU起源癌称为「导管」或「小叶」造成混淆,需修正为基于解剖起源部位的命名。
  • 作者指出直径<15 mm且无DAB的AAB长期结局良好至极佳,现行术语倾向于导致这些早期浸润性肿瘤过度治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To use mammographic tumour features (imaging biomarkers) to identify and investigate breast cancers originating from the terminal ductal lobular units (TDLUs) of the breast in order to overcome the confusion arising from the current histopathology terminology, which calls cancers arising from the TDLUs either "ductal" or "lobular".

METHOD: Prospectively collected data from a randomized controlled mammography screening trial with more than four decades of follow up, and data from the subsequent population-based service screening program in Dalarna County, Sweden, provided the database necessary for studying nonpalpable, primarily screen-detected breast cancer cases in their earliest detectable phases. Large format thick (subgross) and thin section histopathologic images of breast cancers originating from the TDLUs were correlated with their mammographic tumour features (imaging biomarkers) and long-term patient outcome.

RESULTS: This systematic correlation indicates that imaging biomarkers can reliably determine the site of origin of breast cancers arising from the terminal ductal lobular units (TDLUs). This breast cancer subgroup has four specific mammographic tumour features: the in situ carcinomas developing from the TDLUs appear as powdery or crushed stone-like calcifications, while the invasive carcinomas appear as stellate/spiculated or circular/oval shaped tumour masses. These features are easily identified with breast imaging, either alone or in combination, unifocal or multifocal. We propose calling breast cancers of TDLU origin acinar adenocarcinoma of the breast (AAB).

CONCLUSIONS: The era of early detection necessitates rectifying the current, confusing histopathological nomenclature to one that is based on the anatomical site of origin of breast cancers. Invasive cancers originating from the TDLUs are either stellate/spiculated or circular, irrespective of the complex WHO histopathologic terminology. The mortality reduction accomplished by participation in mammography screening is mostly accomplished by identifying and treating the AABs in their non-palpable, early phase. AABs detected when < 15 mm diameter with no associated carcinoma originating from the major lactiferous ducts (ductal adenocarcinoma of the breast, DAB) have a good to excellent long-term outcome, irrespective of the current terminology, which tends to lead to overtreatment of these early invasive tumours. The conventionally used prognostic factors, including immunohistochemical biomarkers, fail to identify those 1-14 mm invasive AABs tumours that are eventually fatal. This identification can be made preoperatively by including the characteristic mammographic tumour features, imaging biomarkers, in primary diagnosis, treatment planning, and predicting long-term patient outcome. Forthcoming articles will address breast malignancies originating from structures of the breast other than the TDLUs.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Tabár, Dean, Tucker, et al. Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB. Eur J Radiol. 2022. PMID: 35576721. doi:10.1016/j.ejrad.2022.110323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。